Quality, purity, and safety of BIOVEN MONO correspond with the European Pharmacopoeia regulations for the finished product and raw materials Using the method of ion-exchange chromatographic purification relates these medicines to the last (4th) generation of IVIG, due to BIOVEN MONO have a high safety profile Contains more than 99% of structurally and functionally complete molecules of monomeric IgG 2 validated stages of virus inactivation, including solvent-detergent (SD) treatment. SD is the gold standard of virus inactivation Donors were examined for the absence of antigen and antibodies to HIV 1,2, HCV; plasma pools were tested by IFA for the absence of HBsAg, antigen, and antibodies to HIV 1,2, antibodies to HBV and PCR method for the HCV, HBV NA. Parvovirus B-19 and HIV 1,2 Ready to use Officially approved for use in newborns, pregnant women Indications: cytopenia of various genesis; thrombocytopenic purpura (TP); severe forms of bacterial - toxic and viral infections; polyneuropathy; primary and secondary immunodeficiencies; autoimmune diseases.
50%(50mg/mL) Solution for Infusion (IV)